Beam Therapeutics to Present New Preclinical Data on Base Editing Programs for Hemoglobinopathies at ASH 2019
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 21, 2019--
Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced that it will present preclinical data for the company’s programs addressing sickle cell disease and beta thalassemia, two blood disorders that lack effective, disease-modifying treatments, at the 61 st Annual American Society of Hematology (ASH) Annual Meeting, being held December 7-10, 2019 in Orlando, Fla.
Details of the new data being presented in a poster at ASH are as follows:
Title: Complementary base editing approaches for the treatment of sickle cell disease and Beta-thalassemia
Date & Time: Sunday, December 8, 2019, 6:00-8:00 p.m. ET
Poster Session: 801 – Gene Therapy and Transfer: Poster II
Location: Orange County Convention Center, Hall B
Presenter: Ling Lin, Ph.D., senior scientist II, Beam Therapeutics
About Beam Therapeutics
Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Beam is headquartered in Cambridge, Massachusetts. For additional information, visit www.BeamTx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191121005637/en/
THRUST Strategic Communications
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH STEM CELLS GENETICS OTHER HEALTH PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Beam Therapeutics
Copyright Business Wire 2019.
PUB: 11/21/2019 10:05 AM/DISC: 11/21/2019 10:05 AM